Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Report Overview
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL). The subtypes of NHL are defined by the cell of origin, the location involved, and the extensive histopathologic, immunophenotypic, and genetic criteria. B-cell NHLs generally arise in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to distant sites such as the lung or brain in the later stages of the disease.
Key Mechanism of Action (Marketed) | · Cytotoxic
· Receptor Agonist · Receptor Antagonist · Protein and Peptide Inhibitor · Genes, Nucleic Acids & Related Components Inhibitor |
Key Routes of Administration (Marketed) | · Injection
· Oral · Topical |
Key Molecule Types (Marketed) | · Biologic
· Small molecules |
The Diffuse Large B-Cell Lymphoma (DLBCL) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, and late-to-mid-stage pipeline products with Phase transition success rate (PTSR) and the likelihood of approval (LoA) for Diffuse Large B-Cell Lymphoma (DLBCL). The report also analyzes the clinical and commercial landscapes of DLBCL, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.
Key Mechanisms of Action (Pipeline) | · Cytotoxic
· Biological Factor Inhibitor · Enzyme Inhibitor · Receptor Inhibitor · Receptor Agonist |
Key Routes of Administration (Pipeline) | · Injection
· Oral · Suppository · Topical |
Key Molecule Types (Pipeline) | · Biologic
· Small molecules · Oligonucleotides |
Top Sponsors (Marketed and Pipeline Drugs) | · National Cancer Institute US
· F. Hoffmann-La Roche Ltd · Beigene Ltd · Novartis AG · Abbvie Inc · Celgene Corp |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
DLBCL Marketed Drugs Segmentation by Mechanisms of Action
Cytotoxic, receptor agonist, receptor antagonist, protein and peptide inhibitor, and genes, nucleic acids & related components inhibitor are the key MoA in the DLBCL marketed drugs market. Most marketed drugs for DLBCL are cytotoxic, targeting proteins such as CD19 or CD20.
DLBCL Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)
Buy Full Report to Know More about the MoA of DLBCL Marketed Drugs
DLBCL Marketed Drugs Segmentation by Routes of Administration
The key routes of administration for DLBCL marketed drugs are injection, oral, suppository, and topical. In 2023, most of the marketed drugs available for DLBCL are given by injection.
DLBCL Marketed Drugs Analysis by Routes of Administration, 2023 (%)
Buy Full Report to Know More about the RoA of DLBCL Marketed Drugs
DLBCL Marketed Drugs Segmentation by Molecule Types
The key molecule types for DLBCL marketed drugs are biologic and small molecules. Biologic is leading in the market.
DLBCL Marketed Drugs Analysis by Molecule Types, 2023 (%)
Buy Full Report to Know More about the Molecule Types of DLBCL Marketed Drugs
DLBCL Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action for DLBCL pipeline drugs are cytotoxic, biological factor inhibitor, enzyme inhibitor, receptor inhibitor, and receptor agonist among others. In 2023, most of the drugs in the DLBCL pipeline are cytotoxic.
DLBCL Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy Full Report to Know More about the MoA of DLBCL Pipeline Drugs
DLBCL Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration for DLBCL pipeline drugs are injection, oral, and topical. Most pipeline drugs for DLBCL are injection therapies.
DLBCL Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy Full Report to Know More about the RoA of DLBCL Pipeline Drugs
DLBCL Pipeline Drugs Market Segmentation by Molecule Types
Most pipeline drugs for DLBCL are biologic, followed by small molecules. Oligonucleotide molecules in development are fewer in number and in earlier stages of development.
DLBCL Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy Full Report to Know More About the Molecule Types of DLBCL Pipeline Drugs
DLBCL Marketed and Pipeline Drugs Market – Competitive Landscape
Some of the top sponsors in the DLBCL marketed and pipeline drugs market are the National Cancer Institute US, F. Hoffmann-La Roche Ltd, Beigene Ltd, Novartis AG, Abbvie Inc, and Celgene Corp, among others. In 2023, the National Cancer Institute US leads among the trial sponsors after adding up all the trial phases.
DLBCL Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy the Full Report for More Sponsor Insights into the DLBCL Marketed and Pipeline Drugs Market Download a Free Report Sample
Segments Covered in the Report
DLBCL Marketed Drugs Mechanism of Action (Number of Drugs, 2023)
- Cytotoxic
- Receptor Agonist
- Receptor Antagonist
- Protein and Peptide Inhibitor
- Genes, Nucleic Acids & Related Components Inhibitor
DLBCL Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Topical
DLBCL Marketed Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologics
- Small molecules
DLBCL Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Cytotoxic
- Biological Factor Inhibitor
- Enzyme Inhibitor
- Receptor Inhibitor
- Receptor Agonist
DLBCL Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Injection
- Oral
- Suppository
- Topical
DLBCL Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologics
- Small molecules
- Oligonucleotides
Scope
Components of the report include –
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the DLBCL market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DLBCL market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which is the leading MoA for DLBCL marketed drugs?
In 2023, most of the marketed drugs for DLBCL are cytotoxic.
-
Which is the leading RoA for DLBCL marketed drugs?
In 2023, most of the marketed drugs for DLBCL are injection therapies.
-
Which is the leading MoA for DLBCL pipeline drugs?
In 2023, most of the DLBCL pipeline drugs are cytotoxic.
-
Which is the leading RoA for DLBCL pipeline drugs?
In 2023, most of the drugs in the DLBCL pipeline are injection therapies.
-
In 2023, most of the drugs in the DLBCL pipeline are injection therapies.
In 2023, most of the pipeline drugs for DLBCL are biologic.
-
Who are the top sponsors for DLBCL marketed and pipeline drugs market?
Some of the top sponsors in the DLBCL marketed and pipeline drugs market are the National Cancer Institute US, F. Hoffmann-La Roche Ltd, Beigene Ltd, Novartis AG, Abbvie Inc, and Celgene Corp, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.